Acer Therapeutics (ACER)
(Real Time Quote from BATS)
$0.66 USD
-0.14 (-17.95%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 41 - 60 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-801 Proof-of-Concept Trial in VMS Initiated; Reiterate Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Starts ACER-801 Phase 2a in Menopausal Motor Symptoms, Recent Cash Raise
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Gearing Up for the ACER-001 PDUFA Date in June; Reiterate Buy Rating and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
4Q21: Awaiting ACER-001 June Approval & 2H22 Launch, Other Trials Progress
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Assuming Coverage With a Buy Rating and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
FDA Clears IND for ACER-801 to Treat Induced Vasomotor Symptoms
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
3Q21: ACER-001 Progressing To Our Expected Mid-2022 Approval & 2H22 Launch
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Receives USPTO Allowance of Key ACER-001 Formulation Patent - 2036 Expiry
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
FDA Accepts ACER-001 NDA Filing for Review - Late 2Q22 PDUFA Date
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
2Q21: ACER-001 NDA Submitted & Its Acceptance Will Trigger a $10M Payment
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Defines EDSIVO Clinical Path Forward with FDA Buy In After Type B Meeting
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J